A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Completed · Phase 2

Conditions studied: Anemia

In brief

This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.

Key facts

Study ID

NCT00048035

Run by

Hoffmann-La Roche

People needed

91

Starts

2002-03-01

Expected to finish

2005-06-01

Last updated by the study team

2016-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients >=18 years of age;
• chronic renal anemia;
• on hemodialysis therapy for at least 3 months;
• receiving iv epoetin alfa during the 2 weeks prior to the run-in period.

You may not qualify if…

• women who are pregnant, breastfeeding or using unreliable birth control methods;
• use of any investigational drug within 30 days of the run-in phase, or during the run-in or study treatment period.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Los Angeles, California, United States
• Study site — Maywood, Illinois, United States
• Study site — Louisville, Kentucky, United States
• Study site — Detroit, Michigan, United States
• Study site — Detroit, Michigan, United States
• Study site — Brooklyn Center, Minnesota, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Paterson, New Jersey, United States
• Study site — Brooklyn, New York, United States
• Study site — Mineola, New York, United States
• Study site — New York, New York, United States
• Study site — Nashville, Tennessee, United States
• Study site — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.